Originalarbeiten:

2024
1) Kraus FM, Traut A, Nilius G, Volmerig J, Koziorowski A, Stöver I, Grabellus F, Stahl M, Christoph DC (2024): Pulmonary adenocarcinoma with enteric differentiation (PAED) without TTF-1 expression is a very rare subtype with limited treatment options and poor prognosis. Oncology in Druck.

2) Ferentinos K, Traut A, Gubelt L, Nilius G, Czyborra PB, Nusch A, Langer W, Nückel H, Hannig CV, Stahl M, Christoph DC (2024): Effectiveness and Safety of Docetaxel in Combination with Nintedanib or Ramucirumab Following Chemoimmunotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer. J Oncol Res Ther 9: 10232. DOI: 10.29011/2574-710X.10232.

3) Kraus FM, Traut A, Gubelt L, Nilius G, Volmerig J, Koziorowski, Stöver I, Grabellus F, Stahl, M, Christoph DC (2024) Comparison of Single Agent Check-Point Inhibitors as First-Line Treatment in NSCLC Patients with High PD-L1-Expression. J Oncol Res Ther 9: 10228.

4) Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N (2024): Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R. ESMO Open 9(6):103464.

5) Neal J, Pavlakis N, Kim S-W, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, Lin Y-C, Huseni M, Ballinger M, Graupner V, Curran D, Vervaet P, Newsom-Davis T (2024): CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol 42(20):2393-2403.

2023
1) Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He H, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators (2023): SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Ann Oncol 35(1):66-76.

2) Borchert S, Mathilakathu A, Nath A, Wessolly M, Mairinger E, Kreidt D, Steinborn J, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Mairinger FD (2023). Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model. Int J Mol Sci. 24(15):12426.
3) Stahl MK, Ertl SW, Engelmeyer P, Heuer HC, Christoph DC (2023): Impact of Geriatric Assessment on the Tolerability of Combination Chemotherapy in Older Patients with Advanced Cancer: A Matched-Pair Analysis. Oncol Res Treat. 46(3):100-105.

2022
1) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022): Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. J Thorac Oncol. 18:181-193

2) Zhang Z, Xie S, Cai W, Hong ZN, Yang C, Lin Y, Zhu J, Lin Z, Christoph DC, Bohnenberger H, Kepka L, Brueckl WM, Van Houtte P, Kang M, Lin J (2022): A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer. Transl Lung Cancer Res. 11(1):75-86.

2021
1) Mathilakathu A, Borchert S, Wessolly M, Mairinger E, Beckert H, Steinborn J, Hager T, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Schmid KW, Walter RFH, Brcic L, Mairinger FD (2021): Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study. Transl Lung Cancer Res 10(7):3030-3042.

2) Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, Waller CF, Thomas M, Eggert J, Schmid-Bindert G, Hoiczyk M, Christoph DC, Kimmich M, Deuß B, Seifert S, Held S, Schuler M, Herold T, Breitenbuecher F, Eberhardt WEE (2021): A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 13:1758835921996506.

3) Zeuschner P, Hölters S, Stöckle M, Seliger B, Mueller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm MO, Brüning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-Rüd I, Staehler M, Junker K (2021): Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers (Basel) 13(11):2594.
4) Brcic L, Mathilakathu A, Walter RFH, Wessolly M, Mairinger E, Beckert H, Kreidt D, Steinborn J, Hager T, Christoph DC, Kollmeier J, Mairinger T, Wohlschlaeger J, Schmid KW, Borchert S, Mairinger FD (2021): Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity. Cancers (Basel) 13(8):1761.

5) Ferdinandus J, Metzenmacher M, Kessler L, Umutlu L, Aigner C, Karl KO, Grünwald V, Eberhardt W, Fendler WP, Herrmann K, Faehling M, Christoph DC (2021): Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. J Immunother Cancer 9(3):e002262.

6) Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F. (2021): Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 13:1758835920980558.

2020
1)Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC (2020). Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP. Data Brief 34:106556.

2)Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC (2020): Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 150:114-122.

3)Staehler M, Stöckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Brüning F, Goebell PJ, Augustin M, Roos F, Benz-Rüd I, Marschner N, Grünwald V (2020): Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. Int J Cancer, 148(7):1685-1694.

4)Jia Z, Wang Y, Cao L, Wang Y, Song Y, Yang X, Bing Z, Cao Z, Liu P, Zhang S, Chen Z, Huang M, Yu Y, Han-Zhang H, Song J, Christoph DC, Passaro A, Gridelli C, Hishida T, Liang N, Li S (2020): First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. J Thorac Dis. 12(7):3764-3773.

5)Ferdinandus J, Barbato F, Chodyla M, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Umutlu L, Herrmann K, Christoph DC (2020): Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. J Nucl Med., 62(2):191-194.

2019
1)Walter RFH, Sydow SR, Berg E, Kollmeier J, Christoph DC, Christoph S, Eberhardt WEE, Mairinger T, Wohlschlaeger J, Schmid KW, Mairinger FD (2019): Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma. Cancer Manag Res. 11:8711-8720.

2)Krefting F, Basara N, Schütte W, Späth-Schwalbed E, Alt J, Thiel S, Kimmich G, Fischer JR, Kurz S, Griesinger F, Christoph DC (2019): Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer. J Cancer Res Clin Oncol. 42(5):243-255.

3Walter RFH, Vollbrecht C, Werner R, Borchert S, Schmeller J, Mairinger E, Herold T, Streubel A, Christoph DC‎, Mairinger T, Schmid KW, Wohlschläger J, Hager T, Mairinger F (2019): Processing escape mechanisms through altered proteasomal cleavage of epitopes affect immune response in pulmonary neuroendocrine tumors. Technol Cancer Res T, 17: 1533033818818418.

4)Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Herold T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Aigner C, Schmid KW, Mairinger FD (2019): Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer 19(1):108.

2018
1)Stratmann JA, Michels S, Hornetz S, Christoph DC, Sackmann S, Spengler W, Bischoff H, Schäfer M, Alt J, Müller A, Laack E, Kimmich M, Griesinger F, Sebastian M (2018): Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. J Cancer Res Clin Oncol. 144(12):2457-2463.

2)Oezkan F, Herold T, Darwiche K, Eberhardt WEE, Worm K, Christoph DC, Wiesweg M, Freitag L, Schmid KW, Theegarten D, Hager T, Koenig MJ, He K, Taube C, Schuler M, Breitenbuecher F. (2018): Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma. Clin Lung Cancer. 19(6):e879-e884.

3)Walter RFH, Werner R, Wessolly M, Mairinger E, Borchert S, Schmeller J, Kollmeier J, Mairinger T, Hager T, Bankfalvi A, Christoph DC, Eberhardt WEE, Plönes T, Aigner C, Schmid KW, Wohlschlaeger J, Mairinger FD (2018): Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53. J Oncol. 2018:1986982.

4)Mairinger FD, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Jasani B, Schmid KW, Bankfalvi A (2018): Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. Oncotarget. 9(32):22254-22268.

2017
1)Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E (2017): Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 35(24):2781-2789.

2)Welter S, Arfanis E, Christoph D, Hager T, Roesel C, Aigner C, Weinreich G, Theegarten D (2017): Growth patterns of pulmonary metastases: should we adjust resection techniques to primary histology and size? Eur J Cardiothorac Surg. 52(1):39-46.

3)Mairinger FD, Werner R, Flom E, Schmeller J, Borchert S, Wessolly M, Wohlschlaeger J, Hager T, Mairinger T, Kollmeier J, Christoph DC, Schmid KW, Walter RFH (2017): miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch. 470(6):627-637.

4)Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH (2017): Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma. Oncotarget. 8(23):37502-37510.

5)Wiesweg M, Eberhardt WE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, Kühl H, Stuschke M, Schmid KW, Schuler M (2017): High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. J Thorac Oncol. 12 (1):54-64.

2016
1)Metzenmacher M & Christoph DC (2016): Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer. J Thorac Dis. 8 (10), E1254-E1256.

2)Walter RF, Werner R, Vollbrecht C, Hager T, Flom E, Christoph DC, Schmeller J, Schmid KW, Wohlschlaeger J, Mairinger FD (2016): ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology. PLoS One. 11 (11), e0165181.

3)Walter RF, Vollbrecht C, Werner R, Mairinger T, Schmeller J, Flom E, Wohlschlaeger J, Barbetakis N, Paliouras D, Chatzinikolaou F, Adamidis V, Tsakiridis K, Zarogoulidis P, Trakada G, Christoph DC, Schmid KW, Mairinger FD (2016): Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. J Cancer 7(13):1915-1925.

4)Walter RF, Mairinger FD, Werner R, Vollbrecht C, Hager T, Schmid KW, Wohlschlaeger J, Christoph DC (2016): Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. Oncotarget 7(15):20166-79.

5)Walter RF, Vollbrecht C, Werner R, Wohlschlaeger J, Christoph DC, Kurt Werner S, Mairinger FD (2016): microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. Oncotarget. 7(14):18713-18721.

6)Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D. (2016): Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 44:42-50.

2015
7)Vollbrecht C, Werner R, Walter RF, Christoph DC, Heukamp LC, Peifer M, Hirsch B, Burbat L, Mairinger T, Kurt Werner S, Wohlschlaeger J, Mairinger FD (2015): Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group. Br J Cancer 113(12):1704-1711.

8)Oezkan F, Khan AM, Hager T, Freitag L, Christoph D, Darwiche K (2015): OSNA: A Fast Molecular Test Based on CK19 mRNA Concentration for Assessment of EBUS-TBNA Samples in Lung Cancer Patients. Clin Lung Cancer. 17(3):198-204.

9)Walter RF, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Christoph DC, Zarogoulidis K, Schmid KW, Zarogoulidis P, Wohlschlaeger (2015): SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString). J. Future Oncol. 11(7):1027-1036.

10)Reis H, Herold T, Ting S, Worm K, Huber U, Christoph DC, Eberhardt WE, Kostbade K, Kasper S, Stamatis G, Welter S, Darwiche K, Karpf-Wissel R, Theegarten D, Schmid KW, Schuler M, Wiesweg M (2015): HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. Lung Cancer 88(1):34-41.

11)Walter RF, Mairinger FD, Ting S, Vollbrecht C, Mairinger T, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J (2015): MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br J Cancer 112(5):883-890.

12)Walter RF, Werner R, Ting S, Vollbrecht C, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J, Mairinger FD (2015): Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis. Oncotarget. 6(28):24690-24698.

2014
1)Mairinger FD, Walter RF, Theegarten D, Hager T, Vollbrecht C, Christoph DC, Worm K, Ting S, Werner R, Stamatis G, Mairinger T, Baba H, Zarogoulidis K, Huang H, Li Q, Tsakiridis K, Zarogoulidis P, Kurt Werner S & Wohlschlaeger J (2014): Gene expression analysis of the 26S proteasome subunit PSMB4 reveals significant upregulation, different expression and association with proliferation in human pulmonary neuroendocrine tumours. J Cancer 5(8):646-654.

2)Darwiche K, Özkan F, Ting S, Johnen G, Brüning T, Soltermann A, Huber LC, Christoph DC, Freitag L & Franzen D (2014): Prätherapeutische Biomarker des Lungenkarzinoms unter besonderer Berücksichtigung der Bronchoskopie [Role of pretherapeutic biomarkers in lung cancer with special regards to bronchoscopic procedures]. Pneumologie 68 (11), 719-726.

3)Mairinger FD, Walter RF, Werner R, Christoph DC, Ting S, Vollbrecht C, Zarogoulidis K, Huang H, Li Q, Schmid KW, Wohlschlaeger J & Zarogoulidis P (2014): Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis. J Cancer 5 (6), 465-471.

4)Mairinger FD, Walter RF, Ting S, Vollbrecht C, Kollmeier J, Griff S, Hager T, Mairinger T, Christoph DC, Theegarten D, Kurt Werner S & Wohlschlaeger J (2014): Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma. Future Oncol. 10 (6), 995-1005.

5)Christoph DC, Reyna-Asuncion B, Hassan B, Tran C, Maltzman JD, O’Shannessy DJ, Gauler TC, Wohlschlaeger J, Schuler M, Eberhardt WE & Hirsch FRH (2014). Assessment of Folate Receptor alpha and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non-Small Cell Lung Cancer Patients Clin Lung Cancer 15 (5), 320-330.

6)Mairinger FD, Ting S, Werner R, Walter RF, Hager T, Vollbrecht C, Christoph D, Worm K, Mairinger T, Sheu-Grabellus SY, Theegarten D, Schmid KW & Wohlschlaeger J (2014): Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study. Mod Pathol. 27 (12), 1623-1640.

7Nensa F, Stattaus J, Morgan B, Horsfield MA, Soria JC, Besse B, Gounant V, Khalil A, Seng K, Fischer B, Krissel H, Laurent D, Christoph D, Eberhardt WE & Gauler TC (2014): Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer. Future Oncol. 10 (5), 823-333.

8)Christoph DC & Eberhardt WE (2014): Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements. Curr Opin Oncol. 26 (2), 171-181.

2013
1)Eberhardt WEE, Hoiczyk M & Christoph DC (2013): Therapie des Lungenkarzinoms. TumorDiagn u Ther. 34 (8), 449-452.

2)Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW & Christoph DC (2013): ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy. Clin Lung Cancer 14 (5), 558-567.

3)Gauler TC, Christoph DC, Fischer J, Frickhofen N, Huber R, Gonschorek C, Roth K, Giurescu M & Eberhardt WEE (2013): Phase-I study of sagopilone (ZK-EPO) in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer. Eur J Cancer 49 (11), 2461-2468.

4)Christoph DC & Reckamp KL (2013): Intraventricular chemotherapy of leptomeningeal carcinomatosis from lung cancer – a feasible and beneficial treatment option? J Thorac Oncol. 8 (5), 523-524.

5)Welter S, Schwan A, Cheufou D, Darwiche K, Christoph D, Eberhardt W, Weinreich G & Stamatis G. (2013): Midterm changes in quality of life: a prospective evaluation after open pulmonary metastasectomy. Ann Thorac Surg. 95 (3), 1006-1011.

6)Christoph DC, Reyna Asuncion B, Hassan B, Tran C, Maltzman JD, O’Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WEE & Hirsch FR (2013): Significance of folate receptor alpha and thymidylate synthase expression in patients with non-small cell lung cancer treated with pemetrexed. J Thorac Oncol, 9 (1), 19-30.

2012
7) Christoph DC, Reyna Asuncion B, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp C, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WEE & Hirsch FR (2012): Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma. J Thorac Oncol. 7 (9), 1440-1448.

8)Christoph DC, Kasper S, Gauler TC, Loesch C, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Welter S, Stamatis G, Hirsch FR, Schuler M, Eberhardt WEE & Wohlschlaeger J (2012): βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. Br J Cancer. 107 (5), 823-830.

9)Wynes MW, Konopa K, Singh S, Asuncion BR, Ranger-Moore J, Sternau A, Christoph DC, Dzidziuszko R, Jassem J & Hirsch FR (2012). Thymidylate Synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer. J Thorac Oncol. 7 (6), 982-992.

10)Christoph DC, Hoffmann, A-C, Gauler TC, Reyna Asuncion B, Loewendick H, Peglow A, Hassan B, Tran C, Wynes MW, Schuler M, Eberhardt WE & Hirsch FR (2012). Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed. J Thorac Oncol. 7 (4), 766-767.

2011
1)Christoph DC & Schuler M (2011). Plk1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies. Expert Rev. Anticancer Ther. 11 (7), 1117-1132.

2)Christoph DC, Witkowski L, Stattaus J, Poettgen C, Keyvani C, Gauler TC, Schuler M & Eberhardt WEE (2011). Very late and isolated leptomeningeal relapse of a pulmonary adenocarcinoma presenting as dementia. Onkologie 34 (6), 316-320.

2009
1)Christoph DC, Boese D, Johnson KT, Schlosser TW, Hunold P, Baba HA, Erbel R & Philipp S (2009). Heart failure and cardiac involvement as isolated manifestation of familial form of transthyretin amyloidosis resulting from Val30Met mutation with no clinical signs of polyneuropathy. Circ Heart Fail. 2 (5), 512-515.

2004
2)Keiper M, Stope MB, Szatkowski DC, Böhm A, Tysack K, vom Dorp F, Saur O, Oude Weernink PA, Evellin S, Jakobs KH & Schmidt M. Epac- and Ca2+-controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors (2004). J Biol Chem. 279 (45), 46497-46508.

3)Stope MB, vom Dorp F, Szatkowski DC, Böhm A, Keiper M, Nolte J, Oude Weernink PA, Rosskopf D, Evellin S, Jakobs KH & Schmidt M (2004). Rap2B-dependent stimulation of phospholipase C-epsilon by epidermal growth factor receptor mediated by c-Src phosphorylation of RasGRP3. Mol Cell Biol. 24 (11), 4664-4676.

Abstracts und Präsentationen auf Konferenzen:

2024
1) Shah R, Reck M, Grohe C, Christoph DC, Buchmeier EL, Saalfeld FC, Frost N, Kopp H-G, Faehling M, Griesinger F, Roeper J, Hoffknecht P, Kuon J, Luan J, Chesi P, Christopoulos P, Thomas M (2024): Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. J Clin Oncol 42, 2024 (suppl 16; abstr 8085). Posterpräsentation auf der Jahrestagung der American Society of Clinical Oncology.

2) Hautzel H, Metzenmacher M, Bölükbas S, Volmerig J, Nilius G, Kersting D, Moka D, Herrmann K, Christoph D (2024): Tumorvolumetrische Parameter MTV und TLG zur Prädiktion von progressionsfreiem und Gesamt-Überleben beim nicht-resektablen Malignen Mesotheliom unter Doppelimmuntherapie mit Ipilimumab und Nivolumab: Was kann die baseline FDG PET/CT leisten? NuclearMedicine 63 (2), V06. Vortrag auf dem Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin.

3) Christoph D, Metzenmacher M, Bölükbas S, Volmerig J, Nilius G, Moka D, Hautzel H (2024): PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma better than CT. Oncol Res Treat. Volume 47 (Supplement 1), P756. Posterpräsentation auf dem 36. Deutschen Krebskongress.

4) Karthaus M, Christoph D, Lux MP, Hofheinz R-D, Jordan K (2024): Bewertung des Nutzens von NEPA (fixe Kombination von Netupitant/Palonosetron) zur Vorbeugung von durch Chemotherapie ausgelöster Übelkeit und Erbrechen (CINV) bei Patienten mit erhöhtem Emesisrisiko, die eine moderat emetogene Chemotherapie erhalten. Oncol Res Treat. Volume 47 (Supplement 1), P445. Posterpräsentation auf dem 36. Deutschen Krebskongress.

5) Reitnauer L, Evers G, Christoph D, Brückl W, Wiesweg M, Glanemann F, Webendörfer M, Kropf-Sanchen C, Acker F, Schütte W, Hoffknecht P, Kerkhoff A, Mohr M, Lenz G, Frost N, Overbeck T, Sebastian M, Bleckmann A (2024): Recurrence of locally advanced NSCLC after radiochemotherapy and consolidative Durvalumab – A german multicenter retrospective analysis. Oncol Res Treat. Volume 47 (Supplement 1), P947. Posterpräsentation auf dem 36. Deutschen Krebskongress.

6) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph DC (2024): Addressing systemic first line therapy of elderly lung cancer patients is critical. Oncol Res Treat. Volume 47 (Supplement 1), P755. Posterpräsentation auf dem 36. Deutschen Krebskongress.

2023
1) Christoph DCCC, Metzenmacher M, Bölükbas S, Volmerig4 J, Nilius G, Moka D, Hautzel H (2023): PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT. Ann Oncol Volume 34 (Supplement 2): S1135-S1144, 2196P. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

2) Kuon JB, Blasi M, Kokowski K, Faehling4 M, Schuette W, Christoph DCC, Kimmich M, Engel-Riedel W, Fischer JR, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum Büschenfelde C, Griesinger F, Schneider M, Behnisch R, Stenzinger A, Christopoulos P, Thomas M (2023): DURATION: A multicenter randomized phase II trial investigating sequential mono- (mCTX) or doublet-chemotherapy (dCTX) followed by durvalumab (D) in older or frail patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol Volume 34 (Supplement 2): S755-S851, 1442P Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

3) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph DCCC (2023): Challenge of systemic first-line treatment of elderly lung cancer patients. Ann Oncol Volume 34 (Supplement 2): S755-S851, 1483P. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

4) Evers G, Reitnauer LE, Christoph DCCC, Brueckl WM, Wiesweg M, Glanemann F, Webendoerfer M, Kropf C, Acker F, Hund A, Schütte W, Hoffknecht P, Kerkhoff A, Mohr M, Lenz G, Frost N, Overbeck TR, Sebastian M, Bleckmann A (2023): Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab. Ann Oncol Volume 34 (Supplement 2): S746-S754, 1300P. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

5) Karthaus M, Christoph DC, Lux MP, Hofheinz RD, Jordan K (2023): Assessing the Benet of NEPA (Fixed Combination of Netupitant/Palonosetron) for preventing Chemotherapyinduced Nausea and Vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P724. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

6) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph D (2023): Systemic first line treatment of elderly patients with lung cancer: proper choice is difficult. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P453. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

7) Reitnauer L, Evers G, Christoph D, Brückl W, Wiesweg M, Glanemann F, Webendörfer M, Kropf-Sanchen C, Acker F, Schütte W, Hoff¬knecht P, Kerkho¬ A, Mohr M, Lenz G, Frost N, Overbeck T, Sebastian M, Bleckmann A (2023): Relapse after radiochemotherapy and consolidative Durvalumab in Stage III NSCLC – a retrospective analysis in a real-world setting. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P451. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

8) Christoph D, Metzenmacher M, Bölükbas S, Volmerig J, Nilius G, Moka D, Hautzel H (2023): PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P446. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

9) Peters S, Christoph DC, Field JK, Fietkau R, Filippi AR, Garassino M, Garrido P, McDonald F, Mornex F, Markman B, Solomon BJ, Anand S, Chander P, Qiao Y, Girard N (2023): Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFRMutated NSCLC (PACIFIC-R) J Thorac Oncol Volume 18 Issue 11 (Supplement), OA17.03. Vortrag auf der World Conference on Lung Cancer 2023.

10) Neal J, Pavlakis N, Kim S-W, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin A, Palmero R, Antic V, Chun E, Rao Edubilli T, Lin Y-C, Huseni M, Scheffold C, Vervaet P, Newsom-Davis T (2023): CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. Journal of Thoracic Oncology, Volume 18 Issue 4, S39 – S40. Vortrag auf der European Lung Cancer Conference 2023.

2022
1) Girard N, Christoph DCC, Garassino MC, McDonald F, Mornex F, Field JK, Fietkau R, Garrido Lopez P, Haakensen VD, Siva S, Van den Heuvel M, Bar J, Chouaid C, Vercauter P, Chander P, Licour M, Anand S, de Lima ARMD, Filippi ARR (2022): Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III non-small-cell lung cancer (NSCLC): interim analysis from the PACIFIC-R study. Ann Oncol Volume 16 (Supplement 1), O580. Posterpräsentation at the European Society of Medical Oncology Immuno-Oncology Congress 2022.

2) Galuba J, Stöver I, Koziorowski A, Bölükbas S, Nilius G, Christoph D (2022): Safety and efficacy of simultaneously performed radiotherapy in patients with small-cell lung cancer undergoing atezolizumab treatment. Oncol Res Treat. Volume 45 (Supplement 3), P606. Posterpräsentation auf dem 35. Deutschen Krebskongress.

3) Wessolly M, Mathilakathu A, Mairinger E, Nath A, Beckert H, Kreidt D, Klopp N, Hegedüs B, Steinborn J, Hager T, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Borchert S, Schmid KW, FD Mairinger (2022): Signaling pathways linked to activity of cancer-associated fibroblasts lead to cancer progression and increased tumor cell motility in malignant pleural mesothelioma. Oncol Res Treat. Volume 45 (Supplement 3) P416. Posterpräsentation auf dem 35. Deutschen Krebskongress.

4) Kraus F, Nilius G, Bölükbas S, Stöver I, Koziorowski A, Grabellus F, Christoph DC (2022): Clinical and pathological features and prognosis of non-small cell lung cancer (NSCLC) patients with adenocarcinomas without TTF1 and Napsin A expression. Oncol Res Treat. Volume 45 (Supplement 3), P433. Posterpräsentation auf dem 35. Deutschen Krebskongress.

5) Christoph D, Girard N, Smit H.J.M, Sibille A, Mcdonald F, Mornex F, Garassino MC, Filippi AR, Peters S, Field JK, Drageset Haakensen V, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A; Licour M, Garrido P, Fietkau R (2022): Pacific-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy. Oncol Res Treat. Volume 45 (Supplement 3), P256. Posterpräsentation auf dem 35. Deutschen Krebskongress.

6) Gröschel A, Passlick B, Stuschke M., Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph D, Bernhardt C, Reiser M, M.-O. Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2022): Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany – AIO-TRK-0315. Oncol Res Treat. Volume 45 (Supplement 3), P135. Posterpräsentation auf dem 35. Deutscher Krebskongress.

7) Zeuschner P, Hölters S, Stöckle M, Seliger B, Müller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm M-O, Brüning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-Rüd I, Stähler M, Junker K (2022): Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study). Oncol Res Treat. Volume 45 (Supplement 3), P128. Posterpräsentation auf dem 35. Deutschen Krebskongress.

8) Eberhardt W, Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Ludwig P, Hipper A, Chiabudini M, Spring L, Jänicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Sebastian M, Griesinger F, Thomas M (2022): V899 Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Real-World Evidence zu NSCLC Patienten behandelt mit Radiochemotherapie in Deutschland – AIO-TRK-0315. Oncol Res Treat. Volume 45 (Supplement 2), V899. Vortrag auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

9) Sebastian M, Reck M, Fischer R, Christoph DC, Bernhardt C, von der Heyde E, Nusch A, Ludwig P, Hipper A, Hanselmann J, Medinger T, Binninger A, Jänicke M, Christopoulos P, Elender C, Bethge A, Seese B, Gauler T, Waller CF (2022): P327 Erste Real-World Outcome-Daten von Patienten mit SCLC in Deutschland – Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). Oncol Res Treat. Volume 45 (Supplement 2), P327. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

10) Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, Hoffknecht P, Ludwig P, Hipper A, Chiabudini M, Spring L, Jänicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Nusch A, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2022): Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-World Evidence of NSCLC Stage I, II and III in Germany – AIO-TRK-0315. Zentralblatt für Chirurgie 147 (S01). V-130. Vortrag auf der Jahrestagung der DGT.

11) Sebastian M, Reck M, Fischer RN, Christoph DC, Bernhardt C, von der Heyde E, Nusch A, Ludwig P, Hipper A, Hanselmann J, Medinger T, Binninger A, Jänicke M, Christopoulos P, Elender C, Bethge A, Seese B, Gauler TC, Waller C (2022). First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). Ann Oncol. 33 (S7), P1542. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

12) Kuon JB, Blasi M, Kokowsk K, Faehling M, Schuette W, Christoph DC, Kimmich M, Engel-Riedel W, Fischer J, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum Bueschenfelde C, Griesinger F, Schneider M, Behnisch R, Stenzinger A, Christopoulos P, Thomas M (2022): DURATION – a phase II randomized trial in older / frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): Top-line early efficacy endpoints. Ann Oncol. 33 (S7), P1021. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

13) Eberhardt WEE, Passlick B Stuschke M, Groeschel A, Christopoulos P Reck M, Ludwig P, Hipper A, Chiabudini M, Spring L, Jänicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Sebastian M, Griesinger F, Thomas M (2022): Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315. Ann Oncol. 33 (S7), P963. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

14) Stuschke M, Eberhardt W, Passlick B, Groeschel A, Christopoulos P, Reck M, Grah C, Hoffknecht P, Ludwig P, Hipper A, Chiabudini M, Spring L, Jaenicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Nusch A, Sebastian M, Griesinger F, Thomas M (2022): EP05.01-030 CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany – AIO-TRK-0315. J Thorac Oncol. Volume 17, Issue 9, Supplement. EP05.01. Posterpräsentation auf der World Conference on Lung Cancer 2022.

2021
1) Kuon J, Blasi M, Kokowski K, Faehling M, Schütte W, Christoph DC, Kimmich M, Engel-Riedel W, Fischer JR, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum Büschenfelde C, Griesinger F, Fischer von Weikersthal L, Schmidt B, Gleiber W, Kirchen H, Werke M, Rückert A, Fröhling K-P, Schmidtke-Schrezenmeier G, Moulin J-C, Denzlinger C, Bösche M, Grohé C, Bernhard H, Maintz C, Heinrich K, Kern J, Schneider MA, Krisam J, Sternsinger A, Thomas M (2021): Durvalumab in frail and older patients with stage IV non-small cell lung cancer: the randomized phase II DURATION trial. J Cancer Res Clin Oncol. Volume 44 (Supplement 2), ep641. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

2) Galuba JM, Imke S, Koziorowski A, Bölükbas S, Nilius G, Christoph DC (2021): Efficacy and safety of simultaneously performed radiotherapy in patients with small-cell lung cancer undergoing Atezolizumab treatment. Oncol Res Treat. Volume 44 (Supplement 2), ep577. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

3) Kraus F, Nilius G, Bölükbas S, Stöver I, Koziorowski A, Grabellus F, Christoph D (2021): Clinical and pathological features and prognosis of non-small cell lung cancer (NSCLC) patients with adenocarcinomas without TTF1 and Napsin A expression. Oncol Res Treat. Volume 44 (Supplement 2), ep573. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO und SGHSSH.

4) Shah R, Klotz LV, Christoph DC, Ried M, Wehler T, Reck M, Wesseler C, Bethge A, de Wit M, Hoffknecht P, Jürgens J, Kopp H-G, Hackanson B, Waller CF, Reinmuth N, Schneider MA, Krisam J, Christopoulos P, Eichhorn ME, Thomas M (2021): Nivolumab with chemotherapy in pleural mesothelioma after surgery – NICITA. Oncol Res Treat.Volume 44 (Supplement 2), ep253. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

5) Christoph DC, Girard N, Smit HJM, Sibille A, McDonald F, Mornex F, Garassino MC, Filippi AR, Peters S, Field JK, Drageset Haakensen V, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A, Licour M, Garrido P, Fietkau R (2021): Pacific-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with Durvalumab after chemoradiotherapy. Oncol Res Treat.Volume 44 (Supplement 2), V495. Vortrag auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

6) Eberhardt WEE, Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, CRISP Registry Group (2021): Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC Stage II and III in Germany – AIO-TRK-0315: J Cancer Res Clin Oncol. Volume 44 (Supplement 2), V288. Vortrag auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

7) Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph D, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2021): Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany – AIO-TRK-0315. Zentralblatt für Chirurgie 146 (S01). V-122. Vortrag auf der Jahrestagung of the DGT.

8) Kraus F, Nilius G, Bölükbas S, Stöver I, Koziorowski A, Grabellus F, Christoph DC (2021): Clinical and pathological features and prognosis of nonsmall cell lung cancer (NSCLC) patients with adenocarcinomas without TTF1 and Napsin A expression. Ann Oncol. 32 (S5), P1812. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

9) Galuba JM, Stöver I, Koziorowski A, Bölükbas S, Nilius G, Christoph DC (2021): Safety of simultaneously performed radiotherapy in patients with small cell lung cancer undergoing atezolizumab treatment. Ann Oncol. 32 (S5), P1652. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

10) Gröschel A, Passlick B, Stuschke M, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt WEE (2021): Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany – AIO-TRK-0315. Ann Oncol. 32 (S5), P1162. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

11) Girard N, Smit HJM, Sibille A, McDonald F, Mornex F, Garassino MCC, Filippi AR, Peters S, Field JK, Christoph DC, Fietkau R, Haakensen VD, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A, Licour M, Garrido P (2021): PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 32 (S5), MO1171. Mini-Vortrag auf der Jahrestagung der European Society of Medical Oncology.

12) Galuba J, Stöver I, Koziorowski A, Bölükbas S, Nilius G, Christoph D (2021): Safety of Simultaneously Performed Radiotherapy in Patients With Small-Cell Lung Cancer Undergoing Atezolizumab Treatment. J Thorac Oncol. Volume 16, Issue 10, Supplement 1. P63.10. Posterpräsentation auf der World Conference on Lung Cancer 2021.

13) Kraus F, Nilius G, Bölükbas S, Stöver I, Koziorowski A, Grabellus F, Christoph D (2021): Pathological Features & Prognosis of NSCLC Patients With Enteric Adenocarcinomas Without Expression of TTF-1 and Napsin A. J Thorac Oncol. Volume 16, Issue 10, Supplement 1. P56.04. Posterpräsentation auf der World Conference on Lung Cancer 2021.

14) Stuschke M, Passlick B, Gröschel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt WE (2021): Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Erste Real-World Evidence zu NSCLC Stadium II und III in Deutschland – AIO-TRK-0315 (#175). Strahlentherapie und Onkologie Volume 197, supplement issue 1. VS01-2. Vortrag auf der Jahrestagung der DEGRO.

15) Christoph DC, Ferdinandus J, Metzenmacher M, Kessler P, Umutlu L, Aigner C, Kambartel K-O, Grünwald V, Eberhardt WEE, Fendler WP, Herrmann K, Faehling M (2021). Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapy. Journal of Clinical Oncology 39:15 (supplement) 9050-9050. Posterdiskussion auf der Jahrestagung der American Society of Clinical Oncology.

16) McDonald F, Mornex F, Garassino MC, Filippi AR, Christoph D, Haakensen VD, Agbarya A, Van den Heuvel M, Vercauter P, Chouaid C, Pichon E, Siva S, Steinbusch L, Peretz I, Solomon B, Decoster L, Sawyer W, Allen A, Licour M, Girard N (2021): PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. J Thorac Oncol. Volume 16, Issue 4, Supplement 1. MO79. Mini-Vortrag auf der European Lung Cancer Conference 2021.

2020
1)Shah R, Klotz LV, Feißt M, Schneider M, Kriegsmann M, Ried M, Wesseler C, Christoph DC, de Wit M, Jürgens J, Kopp H-G, Wehler T, Reck M, Sackmann S, Waller C, Reinmuth N, Bischoff H, Winter H , Eichhorn M, Thomas M (2020): NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery. Ann Oncol. 31 (S4), TiP1912. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

2)Christoph DC, Rizzo F, Kambartel K-O, Winke S, Panse J, Abdulla DS, Scheffler M, Azeh IT, Hoiczyk M, Turki A, Metzenmacher M (2020): Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence. Ann Oncol. 31 (S4), P1374. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

3)Christoph DC, Barbato F, Chodyla M-K, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Herrmann K, Ferdinandus J (2020): Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. Ann Oncol. 31 (S4), MO1896. Mini-Vortrag auf der Jahrestagung der European Society of Medical Oncology.

4)Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska -Lange A, Aries SP, Sackmann S, Schuett P, Steger F, Christoph D (2020): Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP) Ann Oncol. 31 (S4), P1244. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

5)Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, Pérol M, Merle P, Sibille A, Markman B, Bouchaab H, Moskovitz M, Schumann C, Gregorc V, Klein AB, Diaz Perez I, Sawyer W, Licour M, Christoph D (2020): Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 31 (S4), P1242. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

6)Ferdinandus J, Barbato F, Chodyla M, Fendler W, Kessler L, Metzenmacher M, Krefting F, Hager T, Herrmann K, Christoph D (2020): PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab. Journal of Nuclear Medicine 61 (supplement 1) 243. Posterpräsentation auf der Jahrestagung der Society of Nuclear Medicine and Molecular Imaging 2020.

2019
1)Christoph D, Behringer D, Emde TO, Goekkurt E, Hinske C, Laack E, Müller-Hüssmann H, Schlenska-Lange A, Schütt P, Schumann C, Seese B, Fietkau R (2019): PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. Oncol Res Treat 42 (Suppl. 4), P757. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

2)Girard N, Mornex F, Christoph D, Fietkau R, Filippi A, Field J, Garrido Lopez P, McDonald F, Peters S, Klein A , Licour M, Garassino M (2019): PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. TiP 101. Posterpräsentation auf der European Lung Cancer Conference 2019.

3)Christoph DC, Gettinger, S, Beck JT, Yang X, Telivala B, Morgensztern B, Velcheti V, Ramalingam S, Schalper K, Dajee M, Ranck A, Yang R, Spigel DR (2019): CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Der Pneumologe, P618. Posterpräsentation auf der Jahrestagung der DGP.

2018
1)Staehler M, Christoph D, Stöckle M, Harde J, Stenzl A, Klein D, Benz-Rüd I, Grünwald V (2018): Final results of phase IV study MARC-2: everolimus after failure of one prior VEGFR-tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. J Cancer Res Clin Oncol. Volume 41 (Supplement 4), P610. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

2)Nadjm S, Exner JP, Gauler T, Pöttgen C, Darwiche K, Cheufou D, Krebs B, Metzenmacher M, Oezkan F, Rebmann V, Umutlu L, Deusch C, Li Y, Lahner H, Christoph D, Hoiczyk M, Witzke O, Hoffmann AC, Aigner C, Theegarten D, Taube C, Schuler M, Stamatis G, Stuschke M, Eberhardt W (2018): Long-term Survival(LTS) and Survivorship Program(SS-P) of Lung Cancer(LC) Patients(Pts). Investigations(Invest) on LT-toxicities(Tox) and late morbidities(Morb). J Cancer Res Clin Oncol. Volume 41 (Supplement 3), P436. Posterpräsentation auf dem 33. Deutscher Krebskongress.

3)Mairinger F, Schmeller J, Wessolly M, Mairinger E, Borchert S, Kollmeier J, Hager T, Mairinger T, Christoph D, Walter R, Plönes T, Wohlschläger J, Jasani B, Schmid KW, Bankfalvi A (2018): Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. J Cancer Res Clin Oncol. Volume 41 (Supplement 3), P406. Posterpräsentation auf dem 33. Deutscher Krebskongress.

4)Mairinger F, Meier S, Wessolly M, Köhler C, Wagner F, Mairinger E, Schmeller J; Borchert S; Wohlschläger J, Plönes T, Hager T, Rozynek P, Kollmeier J, Christoph D, Schmid KW, Mairinger T, Johnen G, Walter R (2018): OncMass Spectrometry based Methylation Analysis of MDM2, CDKN2A, RB1, TP53 and TP73 and Associations to MDM2 Overexpression in Malignant Pleural mesothelioma. J Cancer Res Clin Oncol. Volume 41 (Supplement 3), P404. Posterpräsentation auf dem 33. Deutscher Krebskongress.

5)Mairinger FD, Schmeller J, Wessolly M, Mairinger E, Borchert S, Kollmeier J, Hager T, Christoph DC, Walter RFH, Eberhardt W, Plönes T, Wohlschläger J, Jasani B, Schmid KW, Bankfalvi A (2018): Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. Pathologe 39 (suppl. 1), AG03.P.09. Posterpräsentation auf der Jahrestagung der DGP.

6)S. Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC; Walter RF, Bankfalvi A, Eberhardt WEE, Plönes T, Wohlschläger J, Aigner C, Schmid KW, Mairinger FD (2018): BRCAness Phänotyp als potentieller prädiktiver Marker für neue Therapie-Strategien beim Malignen Pleuramesotheliom. Pathologe 39 (suppl. 1), AG03.P.08. Posterpräsentation auf der Jahrestagung der DGP.

7)Wessolly M, Schmeller J, Mairinger E, Borchert S, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes8 T, Wohlschläger J, Schmid KW, Bankfalvi A, Mairinger1 FD (2018): miRNA regulation is important for DNA-damage repair and recognition in malignant pleural mesothelioma. Pathologe 39 (suppl. 1), AG-O303. Vortrag auf der Jahrestagung der DGP.

2017
1)Stratmann JA, Hornetz S, Griesinger F, Wolf J, Christoph DC, Sackmann S, Spengler W, Bischoff H, Schäfer M, Alt J, Müller A, Laack E, Kimmich M, Sebastian M (2017): An expanded access program of osimertinib (Tagrisso) in patients with advanced non-small cell lung cancer: data report from Germany. J Cancer Res Clin Oncol. Volume 40 (Supplement 3), P591. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

2)Oezkan F, Herold T, Darwiche K, Eberhardt W, Christoph D, Worm K, Freitag L, Schmid K, Hager T, Breitenbuecher F, Schuler M (2017): Rapid and highly sensitive EGFR del ex19 and KRAS exon 2 mutation detection in EBUS-TBNA sspecimen of lung adenocarcinoma. J Thorac Oncol. Volume 11, Issue 11, Supplement 1. P3.02B-025. Posterpräsentation auf der World Conference on Lung Cancer 2016

3)Mairinger FD, Werner R, Flom E, Vollbrecht C, Schmeller J, Borchert S, Wohlschlaeger J, Mairinger T, Kollmeier J, Christoph DC, Schmid KW, Walter RFH (2017): miRNA regulation is important for DNA-damage repair and recognition in malignant pleural mesothelioma. Pathologe 38 (suppl. 1), P-702. Posterpräsentation auf der Jahrestagung der DGP.

4)Vollbrecht C, Werner R, Walter RFH, Christoph DC, Heukamp, LC, Peifer M, Hirsch B, Burbat L, Mairinger T, Schmid KW, Wohlschlaeger J, Mairinger FD (2017): Mutational analysis of pulmonary tumors with neuroendocrine features using targeted paralell sequencing. Pathologe 38 (suppl. 1), P-0606. Posterpräsentation auf der Jahrestagung der DGP.

5)Garassino M, Rizvi N, Besse B, Jänne P, Christoph D, Peters S, Toh CK, Kurata T, Costa EC, Koczywas M, Felip E, Chaft J, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M (2017): Atezolizumab as 1L therapy for advanced NSCLC in PD-L1–selected patients: updated ORR, PFS and OS data from the BIRCH study. J Thorac Oncol. Volume 12 Issue 1, Supplement 1. OA03.02. Vortrag auf der World Conference on Lung Cancer 2016.

2016
1)Wakelee H, Patel JD, Heist R, Balmanoukian A, Besse B, Felip E, Costa EC, Chow LQ, Koczywas M, Garassino MC, Christoph D, Toh CK, Johnson ML, Chaft J, Kurata T, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger SN, Peters S (2016): Phase II Trial of Atezolizumab for Patients with PD-L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results. J Thorac Oncol. Volume 11, Issue 11, Supplement 1. ORAL01.04. Vortrag auf dem „Chicago Multidisciplinary Symposium in Thoracic Oncology” 2016.

2015
1) Walter RFH, Vollbrecht C, Christoph DC, Werner R, Mairinger T, Theegarten D, Schmid KW, Wohlschlaeger J, Mairinger FD (2015): Investigation of Pharmaceutical Targets in Pulmonary Neuroendocrine Tumors by massive parallel sequencing and digital gene expression analysis. Pathologe 36 (suppl. 1), SO-069. Posterpräsentation auf der Jahrestagung der DGP.

2)Walter RFH, Werner R, Vollbrecht C, Theegarten D, Worm K, Mairinger T, Wohlschlaeger J, Christoph DC, Mairinger FD (2015): Nutlin-3A key players are differentially regulated through miRNAs between MDM2-positive and -negative pleural mesotheliomas. Pathologe 36 (suppl. 1), SO-018. Posterpräsentation auf der Jahrestagung der DGP.

3)Walter RFH, Mairinger F, Werner R, Vollbrecht C, Mairinger T, Worm K, Schmid KW, Christoph DC, Wohlschläger J (2015): Molecular Biological Analysis of Malignant Pleural Mesothelioma. Pathologe 36 (suppl. 1), SO-071. Posterpräsentation auf der Jahrestagung der DGP.

2014
1)Walter RFH, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Stamatis G, Zwanziger D, Eberhardt W, Schuler M, Christoph DC, Freitag L, Schmid KW & Wohlschlaeger J (2014): Screening 80 neuroendocrine lung cancer patients by using the NanoString technology implies several targets for new tailored therapies. Pathologe 35 (suppl. 1), SA-096. Posterpräsentation auf der Jahrestagung der DGP.

2)Walter RFH, Mairinger FD, Ting S, Vollbrecht C, Hager T, Worm K, Eberhardt W, Kollmeier J, Mairinger T, Christoph DC, Schmid KW, Freitag L & Wohlschlaeger J (2014): Inhibition of MDM2 via Nutlin-3—the next therapy for pleural mesothelioma with poor prognosis? Pathologe 35 (suppl. 1), SA-095. Posterpräsentation auf der Jahrestagung der DGP.

3)Mairinger F, Ting S, Werner R, Walter RFH, Hager T, Vollbrecht C, Christoph D, Worm K, Mairinger T, Sheu-Grabellus S-Y, Theegarten D, Schmid KW & Wohlschlaeger J (2014): Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumours of the lung: results of a profiling study. Pathologe 35 (suppl. 1), SA-080. Posterpräsentation auf der Jahrestagung der DGP.

4)Walter RFH, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Stamatis G, Zwanziger D, Eberhardt W, Schuler M, Christoph DC, Freitag L, Schmid KW & Wohlschlaeger J (2014): Is the mRNA expression profile of apoptosis and cell cycle related genes a marker for the aggressiveness of neuroendocrine tumors of the lung? Pathologe 35 (suppl. 1), FR-048. Posterpräsentation auf der Jahrestagung der DGP.

5)Mairinger F, Walter FRH, Werner R, Vollbrecht C, Ting S, Hager T, Schmid KW, Wohlschlaeger J & Christoph D (2014): Folic acid metabolism and DNA-mismatch repair in pulmonary neuroendocrine tumors: identification of potential chemotherapy resistance mechanisms. Pathologe 35 (suppl. 1), FR-044. Posterpräsentation auf der Jahrestagung der DGP.

6)Mairinger F, Walter RFH, Werner R, Ting T, Hager T, Vollbrecht C, Theegarten D, Christoph D, Schmid KW & Wohlschlaeger J (2014): Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carcinomas and is crucial for carcinoid tumorgenesis. Pathologe 35 (suppl. 1), FR-043. Posterpräsentation auf der Jahrestagung der DGP.

2013
1)Mairinger F, Ting S, Vollbrecht C, Walter RFH, Kollmeier J, Grief S, Hager T, Mairinger T, Christoph D, Schmid KW & Wohlschläger J (2013): P53 E3 ubiquitin protein ligase homolog (mouse) (MDM-2) immunoexpression is a strong predictor of poor overall survival in malignant pleural mesothelioma. Pathologe 34 (suppl. 1), FR-103. Posterpräsentation auf der Jahrestagung der DGP.

2)Mairinger F, Ting S, Worm K, Hager T, Wohlschläger J, Schmid KW & Christoph D (2013): LH1, MSH2, MSH6 and ERCC1: DNA-mismatch repair proteins associated with response to platin- based chemotherapy in MPM? Pathologe 34 (suppl. 1), FR-078. Posterpräsentation auf der Jahrestagung der DGP.

3)Mairinger F, Walter RFH, Hager T, Vollbrecht C, Christoph D, Worm K, Ting S, Schmid KW & Wohlschläger J (2013): The proteasome subunits PSMA5 and PSMB4 are potent markers to discriminate between typical and atypical carcinoid tumors of the lung. Pathologe 34 (suppl. 1), DO-036. Vortrag auf der Jahrestagung der DGP.

2012
1)Christoph DC, Reyna Asuncion B, Hassan B, Maltzman J, O’Shannessy D, Gauler TC, Wohlschlaeger J, Wynes MW, Schuler M, Eberhardt WEE & Hirsch FR (2012): Significance of Folate Receptor alpha (FRA) and Thymidylate Synthase (TS) Expression in metastatic Non-Small Cell Lung Cancer Patients treated with Pemetrexed-based chemotherapy. Onkologie 36 (suppl. 6; abstr V125). Vortrag auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

2)Christoph DC, Reyna Asuncion B, Hassan B, Maltzman J, O’Shannessy D, Gauler TC, Wynes MW, Schuler M, Eberhardt WEE & Hirsch FR (2012): Investigation of Folate Receptor alpha and Thymidylate Synthase Proteins Expression in metastatic Non-Small Cell Lung Cancer Patients treated with Pemetrexed-based chemotherapy. J Thorac Oncol 10 (Suppl 2). Vortrag auf dem „Chicago Multidisciplinary Symposium in Thoracic Oncology” 2012.

3)Christoph DC, Reyna Asuncion B, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Welter S, Tran C, Hassan B, Loewendick H, Peglow A, Schuler M, Eberhardt WEE & Hirsch FR (2012): Folylpoly-γ-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC). Abstract 1713. Posterpräsentation auf der Jahrestagung der American Association of Cancer Research.

4)Christoph DC, Reyna Asuncion B, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Welter S, Tran C, Hassan B, Loewendick H, Peglow A, Schuler M, Eberhardt WEE & Hirsch FR (2012): Folylpoly-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC). Poster B6. Posterpräsentation auf der AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine, San Diego, CA, USA.

2011
1)Christoph DC, Kasper S, Gauler TC, Breitenbuecher F, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Schuler M, Hirsch FR, Eberhardt WEE & Wohlschlaeger J (2011): Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer. Eur J Cancer 47 (suppl 4; abstr PP35). Posterpräsentation auf der EORTC-NCI-ASCO Jahrestagung on “Molecular Markers in Cancer”.

2)Gauler TC, Poettgen C, Korfee S, Wagner H, Hepp R, Stamatis G, Christoph DC, Passlick B, Budach V, Seeber S, Wilke H, Stuschke M & Eberhardt W (2011): Long-term survival (LTS) and competing risks within a prospective multicenter German randomized trial comparing induction (IND) chemotherapy (CTx) followed by concurrent (cc) chemoradiation (CTx/RTx) plus surgery (S) (=TRIMODALITY) supplemented by PCI versus local treatment alone (S + RTx) in operable IIIA NSCLC. J Thorac Oncol. 6 (suppl 2; abstr 2575). Mini-Vortrag auf der World Conference on Lung Cancer 2011.

3Poettgen C, Le Pechoux C, Gauler TC, Stuschke M, Grunenwald DH, Stamatis G, Bildat S, Krbek T, Christoph DC, Welter S, Fischer B, Hepp R, Theegarten D & Eberhardt W (2011): 10-year long-term survival (LTS) of induction (IND) chemotherapy (CTx) with three cycles cisplatin(P)/paclitaxel(T) followed by concurrent (cc) chemoradiation (CTx/RTx) P/etoposide (eto)/45 Gy (1.5 Gy bid) plus surgery (S) – a multicenter phase-II trial (CISTAXOL). J Thorac Oncol. 6 (suppl 2; abstr 2.563). Mini-Vortrag auf der World Conference on Lung Cancer 2011.

4)Christoph DC, Mascaux C, Wynes MW, Reyna Asuncion B, Wohlschlaeger J, Theegarten D, Gauler TC, Neumann V, Poettgen C, Tran C, Tannapfel A, Schuler M, Eberhardt WEE & Hirsch FR (2011): Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma. J Thorac Oncol. 6 (suppl 2; abstr 2.480). Posterpräsentation auf der World Conference on Lung Cancer 2011.

5)Eberhardt W, Hepp R, Gauler TC, Christoph DC, Hoffmann A-C, Theegarten D, Welter S, Schmid KW, Wohlschlaeger J, Passlick B, Le Péchoux C, Stamatis G, Stuschke M & Poettgen C (2011): Competing risks analysis and long-term survival (LTS) of patients (pts) with locally advanced (LAD) stage III non-small cell lung cancer (NSCLC) treated on sequential trimodality (TM) trials. J Thorac Oncol 6: 2011 (suppl 2; abstr 2.200). Vortrag auf der World Conference on Lung Cancer 2011.

6)Christoph DC, Wohlschlaeger J, Neumann V, Gauler TC, Poettgen C, Peglow A, Tannapfel A, Schuler M, Hirsch FR, Eberhardt WEE & Theegarten D (2011): Impact of dihydrofolate reductase expression for clinical benefit from pemetrexed in malignant pleural mesothelioma. J Thorac Oncol. 6 (suppl 2; abstr 1.853). Posterpräsentation auf der World Conference on Lung Cancer 2011.

7)Christoph DC, Kasper S, Gauler TC, Breitenbuecher F, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Schuler M, Hirsch FR, Eberhardt WEE & Wohlschlaeger J (2011): Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer. J Thorac Oncol. 6 (suppl 2; abstr 2.227). Posterpräsentation auf der World Conference on Lung Cancer 2011.

8)Christoph DC, Mascaux C, Wynes MW, Reyna Asuncion B, Wohlschlaeger J, Theegarten D, Gauler TC, Schuler M, Eberhardt WEE & Hirsch FR (2011): Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma. J Clin Oncol. 29 (suppl; abstr 7024). Posterdiskussion auf der Jahrestagung der American Society of Clinical Oncology.

9)Christoph DC, Wittkowski L, Stattaus J, Pöttgen C, Keyvani K, Gauler TC, Schuler M & Eberhardt WEE (2011): Very late and isolated leptomeningeal relapse of a pulmonary adenocarcinoma presenting as dementia. Onkologie 34 (suppl. 6; abstr P574). Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

2009
1)Gauler TC, Christoph DC, Gamarra F, Fuhr H-G, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M & Eberhardt WEE (2008): Phase I study of sagopilone (ZK-EPO) in combination with cisplatin in patients with chemotherapy-naive extensive disease small cell lung cancer (ED-SCLC). Ann Oncol. 19 (suppl 1: abstr 331P). Posterpräsentation auf der Jahrestagung der European Cancer Organisation/European Society of Medical Oncology.

2)Christoph DC, Gauler TC, Gamarra F, Fuhr H-G, Fischer JR, Gonschorek C, Frickhofen N, Huber RM, Schuler M & Eberhardt WEE (2009): Phase I trial of sagopilone in combination with cisplatin as 1st-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC). Eur J Cancer Suppl. 7 (abstr Po9142). Posterpräsentation auf der Jahrestagung der European Cancer Organisation/European Society OF Medical Oncology.

3)Gauler TC, Christoph DC, Gamarra F, Fuhr H-G, Fischer JR, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M & Eberhardt WEE (2009): Phase I study of sagopilone (ZK-EPO) in combination with cisplatin in patients with chemotherapy-naïve extensive-disease small-cell lung cancer (ED-SCLC). J Thorac Oncol. 4 (suppl 1; abstr PD4.4.1). Posterdiskussion auf der World Conference on Lung Cancer 2009.

2008
1)Christoph DC, Gauler TC, Gamarra F, Fuhr H-G, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M & Eberhardt WEE (2008): Phase I trial of sagopilone (ZK-EPO) in combination with cisplatin as first-line therapy in patients with extensive disease small-cell lung cancer (ED-SCLC). Onkologie 31 (suppl. 4; abstr V180). Vortrag auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

2004
1)Schmidt M, Stope MB, Szatkowski DC, vom Dorp F, Oude Weernink PA & Jakobs KH (2004): Epac and Ca2+-controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. N-S Arch Pharmacol. 371 (suppl 1; abstr R10). Vortrag auf der DGPT Jahrestagung 2003.

2)Szatkowski DC, Keiper M, Stope MB, Oude Weernink PA, Jakobs KH & Schmidt M (2004): PLC-ε and CalDAG2-mediated activation of Ras and MAP kinases by the β2-Adrenoceptor. N-S Arch Pharmacol. 369 (suppl 1; abstr R203). Vortrag auf der Jahrestagung der DGPT.

2003
1)Szatkowski DC, Böhm A & Schmidt M (2003): Molekulare Mechanismen der CalDAG3- und Rap2B-abhängigen Phospholipase C-e-Stimulation durch EGF. Posterpräsentation auf dem 2. Forschungstag des Universitätsklinikums Essen (11-18-2003).

2)Schmidt M, Keiper M, Böhm A, Evellin S, Sari A, Szatkowski DC, vom Dorp F, OudeWeernink, PA & Jakobs KH (2003): Mechanisms of the CalDAG3- and Rap2B-mediated phospholipase C stimulation by the epidermal growth factor receptor. N-S Arch Pharmacol. 367 (suppl 1; abstr R195). Vortrag auf der Jahrestagung der DGPT.